Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04487873
Recruitment Status : Not yet recruiting
First Posted : July 27, 2020
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Merve Firat, Hacettepe University

Brief Summary:
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

Condition or disease
Covid19 Bronchiectasis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 28 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
Estimated Study Start Date : July 23, 2020
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety Phobias

Group/Cohort
Bronchiectasis
Having been diagnosed with non-cystic fibrosis bronchiectasis
Healthy individuals
Healthy individuals without chronic disease



Primary Outcome Measures :
  1. COVID-19 Phobia [ Time Frame: 5 minutes ]
    COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.

  2. Qol [ Time Frame: 10 minutes ]
    Quality of life was evaluated with Nottingham Health Profile


Secondary Outcome Measures :
  1. Health anxiety [ Time Frame: 10 minutes ]
    Health anxiety was evaluated with Health Anxiety Inventory

  2. Physical activity [ Time Frame: 5 minutes ]
    Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)

  3. Quality of sleep [ Time Frame: 10 minutes ]
    Quality of sleep was evaluated with Pittsburgh Sleep Quality Index



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.
Criteria

Inclusion Criteria:

  • Having been diagnosed with non-cystic fibrosis bronchiectasis
  • No acute bronchiectasis exacerbation or infection in the past 2 weeks
  • Volunteering to participate in the research

Exclusion Criteria:

  • Having a cognitive problem
  • Not being literate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04487873


Contacts
Layout table for location contacts
Contact: Merve Firat, MSc +903123051576 mervefirat@hacettepe.edu.tr

Sponsors and Collaborators
Hacettepe University
Investigators
Layout table for investigator information
Principal Investigator: Merve Firat, MSc Hacettepe University
Study Director: Naciye Vardar-Yagli, PhD Hacettepe University
Study Chair: Deniz İnal-İnce, Professor Hacettepe University
Study Chair: Melda Saglam, PhD Hacettepe University
Study Chair: Ebru Calik-Kütükcü, PhD Hacettepe University
Study Chair: Aslıhan Cakmak, MSc Hacettepe University
Layout table for additonal information
Responsible Party: Merve Firat, Principal Investigator, Hacettepe University
ClinicalTrials.gov Identifier: NCT04487873    
Other Study ID Numbers: GO 20/602
First Posted: July 27, 2020    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Merve Firat, Hacettepe University:
phobia
quality of life
health anxiety
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiectasis
Bronchial Diseases
Respiratory Tract Diseases